Literature DB >> 30725387

Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial.

Bulent Cetinel1, Bulent Onal2, Mehmet Hamza Gultekin2, Muhammed Guzelsoy3, Fethi Ahmet Turegun2, Murat Dincer4.   

Abstract

PURPOSE: To compare the heart rate increase side effect of different antimuscarinic drugs used in overactive bladder (OAB).
METHODS: Overall 341 patients were consecutively randomized to take seven different antimuscarinic drugs between January 2014 and June 2016 at three institutions, and 250 patients who completed the follow-up visits were accepted into this study. Ninety-one patients who never came to visits were excluded. Drugs were classified into two groups as selective (darifenacin hydrobromide, solifenacin succinate and oxybutynin hydrochloride) and non-selective (fesoterodine fumarate, tolterodine tartrate, trospium chloride and propiverine hydrochloride) antimuscarinic drugs. The cardiac pulse rates and the blood pressures were recorded during the baseline, first visit (1 week) and second visit (1 month). Data were compared for drugs and two groups (selective versus non-selective) by using ANOVA test.
RESULTS: Baseline characteristics were similar among the patients using different antimuscarinic drugs. Statistically significant increase in heart rate occurred in patients treated with non-selective antimuscarinic drugs compared to those treated with selective drugs (p < 0.001), and this increase was especially evident in patients treated with trospium chloride, tolterodine tartrate, fesoterodine fumarate and propiverine hydrochloride (p < 0.001, 0.003, 0.011 and 0.37, respectively). There was no statistical difference for the other side effects.
CONCLUSIONS: Our results showed that heart rate significantly increased in OAB patients treated with non-selective antimuscarinic drugs. Trospium chloride, tolterodine tartrate, fesoterodine fumarate and propiverine hydrochloride seem to have the most unfavorable properties with regard to increased heart rate side effect when compared to the other antimuscarinic drugs (darifenacin hydrobromide, solifenacin succinate and oxybutynin hydrochloride).

Entities:  

Keywords:  Antimuscarinics; Cardiovascular system side effects; Muscarinic receptor selectivity; Overactive bladder

Mesh:

Substances:

Year:  2019        PMID: 30725387     DOI: 10.1007/s11255-019-02090-9

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  24 in total

1.  The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Neurourol Urodyn       Date:  2002       Impact factor: 2.696

Review 2.  Muscarinic regulation of cardiac ion channels.

Authors:  Robert D Harvey; Andriy E Belevych
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

Review 3.  Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder.

Authors:  Paul Abrams; Karl-Erik Andersson; Jerry J Buccafusco; Christopher Chapple; William Chet de Groat; Alison D Fryer; Gary Kay; Alan Laties; Neil M Nathanson; Pankaj Jay Pasricha; Alan J Wein
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

4.  Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama study.

Authors:  Atsushi Hozawa; Takayoshi Ohkubo; Masahiro Kikuya; Takashi Ugajin; Junko Yamaguchi; Kei Asayama; Hirohito Metoki; Kaori Ohmori; Haruhisa Hoshi; Junichiro Hashimoto; Hiroshi Satoh; Ichiro Tsuji; Yutaka Imai
Journal:  Am J Hypertens       Date:  2004-11       Impact factor: 2.689

5.  How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study.

Authors:  I Milsom; P Abrams; L Cardozo; R G Roberts; J Thüroff; A J Wein
Journal:  BJU Int       Date:  2001-06       Impact factor: 5.588

6.  Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome.

Authors:  Paul Abrams; Linda Cardozo; Christopher Chapple; Dzelal Serdarevic; Katherine Hargreaves; Vikram Khullar
Journal:  Int J Urol       Date:  2006-06       Impact factor: 3.369

7.  Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow.

Authors:  C R Chapple; P Abrams
Journal:  Eur Urol       Date:  2005-07       Impact factor: 20.096

8.  Prevalence and burden of overactive bladder in the United States.

Authors:  W F Stewart; J B Van Rooyen; G W Cundiff; P Abrams; A R Herzog; R Corey; T L Hunt; A J Wein
Journal:  World J Urol       Date:  2002-11-15       Impact factor: 4.226

9.  Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial.

Authors:  Norman Zinner; Marc Gittelman; Richard Harris; Jacques Susset; Angelo Kanelos; Stephen Auerbach
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

10.  Multicenter phase III trial studying trospium chloride in patients with overactive bladder.

Authors:  Delbert Rudy; Kevin Cline; Richard Harris; Kenneth Goldberg; Roger Dmochowski
Journal:  Urology       Date:  2006-02       Impact factor: 2.649

View more
  4 in total

1.  Heart rate effects of antimuscarinic drugs.

Authors:  W Haverkamp
Journal:  Int Urol Nephrol       Date:  2019-07-27       Impact factor: 2.370

2.  Re: Letter to editor: heart rate effects of antimuscarinic drugs.

Authors:  Bulent Cetinel; Bulent Onal; Mehmet Hamza Gultekin
Journal:  Int Urol Nephrol       Date:  2019-07-27       Impact factor: 2.370

3.  Risk of Mortality Associated with Non-selective Antimuscarinic medications in Older Adults with Dementia: a Retrospective Study.

Authors:  Nandita Kachru; Holly M Holmes; Michael L Johnson; Hua Chen; Rajender R Aparasu
Journal:  J Gen Intern Med       Date:  2020-02-05       Impact factor: 5.128

4.  Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study.

Authors:  Nandita Kachru; Holly M Holmes; Michael L Johnson; Hua Chen; Rajender R Aparasu
Journal:  Curr Med Res Opin       Date:  2021-05-13       Impact factor: 2.705

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.